Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
Digestive Diseases and Sciences|January 10, 2022
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness MethodologyGaurav Syal, Miles P Sparrow, Fernando Velayos, et al.
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
The AAPS Journal|March 15, 2025
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop ReportSophie Shubow, Michele Gunsior, Amy Rosenberg, et al.
The American Journal of Gastroenterology|January 9, 2025
Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b TrialJessica R Allegretti, Adam S Cheifetz, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Digestive Diseases and Sciences|July 4, 2024
Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel DiseaseAlexander Abadir, Angela Troia, Hyder Said, et al.
Annals of Gastroenterology|May 21, 2026
Postpartum nonsteroidal anti-inflammatory drug exposure does not increase risk for flare in patients with inflammatory bowel diseaseLoren G Rabinowitz, Tina Deyhim, Joyce Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Digestive Diseases and Sciences|January 10, 2022
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness MethodologyGaurav Syal, Miles P Sparrow, Fernando Velayos, et al.
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
The AAPS Journal|March 15, 2025
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop ReportSophie Shubow, Michele Gunsior, Amy Rosenberg, et al.
The American Journal of Gastroenterology|January 9, 2025
Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b TrialJessica R Allegretti, Adam S Cheifetz, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Digestive Diseases and Sciences|July 4, 2024
Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel DiseaseAlexander Abadir, Angela Troia, Hyder Said, et al.
Annals of Gastroenterology|May 21, 2026
Postpartum nonsteroidal anti-inflammatory drug exposure does not increase risk for flare in patients with inflammatory bowel diseaseLoren G Rabinowitz, Tina Deyhim, Joyce Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Pageof 21